CLINICAL TRIALS PROFILE FOR ANGIOMAX
✉ Email this page to a colleague
All Clinical Trials for Angiomax
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00043277 ↗ | Study Of Angiomax In Infants Under Six Months With Thrombosis | Completed | The Medicines Company | Phase 2 | 2002-08-01 | The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH). |
| NCT00073580 ↗ | Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) | Completed | The Medicines Company | Phase 3 | 2003-10-01 | The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery. |
| NCT00073593 ↗ | Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB | Completed | The Medicines Company | Phase 3 | 2003-08-01 | The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery. |
| NCT00079508 ↗ | Angiomax in Patients With HIT/HITTS Type II Undergoing CPB | Completed | The Medicines Company | Phase 3 | 2004-04-01 | The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant. |
| NCT00079586 ↗ | Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) | Completed | The Medicines Company | Phase 3 | 2004-04-01 | The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Angiomax
Condition Name
Clinical Trial Locations for Angiomax
Trials by Country
Clinical Trial Progress for Angiomax
Clinical Trial Phase
Clinical Trial Sponsors for Angiomax
Sponsor Name
